|
Aug 4
|
Why Morgan Stanley Upgraded This Biotech Stock to a Buy
|
|
Aug 1
|
Ionis Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations
|
|
Jul 31
|
Ionis Pharmaceuticals Inc (IONS) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
|
|
Jul 30
|
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
|
|
Jul 30
|
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates
|
|
Jul 30
|
Ionis Pharmaceuticals: Q2 Earnings Snapshot
|
|
Jul 30
|
Ionis reports second quarter 2025 financial results and highlights progress on key programs
|
|
Jul 29
|
Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency
|
|
Jul 25
|
TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)
|
|
Jul 25
|
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
|
|
Jul 23
|
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy?
|
|
Jul 21
|
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
|
|
Jun 12
|
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
|
|
Jun 12
|
Ionis doses first subject in Phase III trial of Angelman syndrome therapy
|
|
Apr 16
|
Ionis to hold first quarter 2025 financial results webcast
|
|
Mar 12
|
Ono earmarks $940m to gain rare blood cancer therapy from Ionis
|
|
Mar 12
|
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
|
|
Mar 12
|
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono
|
|
Mar 12
|
Ono pays $280M to license Ionis rare disease drug
|
|
Mar 11
|
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
|